NCT03954158View on ClinicalTrials.gov

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 15, 2019

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions
Atopic Dermatitis
Interventions
DRUG

Crisaborole ointment 2%

BID regimen

DRUG

Vehicle

BID regimen

DRUG

Crisaborole ointment 2%

QD regimen

DRUG

Vehicle

QD regimen

Trial Locations (3)

532-0003

Medical Corporation Heishinkai OPHAC Hospital, Osaka

103-0027

Fukuwa Clinic, Chuo-ku

171-0014

Sekino Hospital, Toshima-ku

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03954158 - Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis | Biotech Hunter | Biotech Hunter